Impact of worsening renal function related to medication in heart failure

H.P. Brunner-La Rocca*, C. Knackstedt, L. Eurlings, V. Rolny, F. Krause, M.E. Pfisterer, D. Tobler, P. Rickenbacher, M.T. Maeder, the TIME-CHF Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

58 Citations (Web of Science)


Aims Renal failure is a major challenge in treating heart failure (HF) patients. HF medication may deteriorate renal function, but the impact thereof on outcome is unknown. We investigated the effects of HF medication on worsening renal function (WRF) and the relationship to outcome. Methods and resultsThis post-hoc analysis of TIME-CHF (NT-proBNP-guided vs. symptom-guided management in chronic HF) included patients with LVEF 45% and 1 follow-up visit (n = 462). WRF III was defined as a rise in serum creatinine 0.5 mg/dL (i.e. 44.2 mu mol/L) at any time during the first 6 months. Four classes of medication were considered: loop diuretics, beta-blockers, renin-angiotensin system (RAS)-blockers, and spironolactone. Functional principal component analysis of daily doses was used to comprehend medication over time. All-cause mortality after 18 months was the primary outcome. Interactions between WRF, medication, and outcome were tested. Patients with WRF III received on average higher loop diuretic doses (P = 0.0002) and more spironolactone (P = 0.02), whereas beta-blockers (P = 0.69) did not differ and lower doses of RAS-blockers were given (P = 0.09). There were significant interactions between WRF III, medicationn and outcome. Thus, WRF III was associated with poor prognosis if high loop diuretic doses were given (P = 0.001), but not with low doses (P = 0.29). The opposite was found for spironolactone (poor prognosis in the case of WRF III with no spironolactone, P
Original languageEnglish
Pages (from-to)159-168
JournalEuropean journal of heart failure
Issue number2
Publication statusPublished - 1 Jan 2015

Cite this